Glaukos® Corporation

Glaukos® Corporation is a valued OOSS Resource Partner. Resource Partners provide products and services that may be of interest to OOSS Members. These partners support OOSS through financial and in-kind contributions. Learn more about the OOSS Partner Program.

 

 

Glaukos®  Corporation is dedicated to researching and developing micro-technologies to improve glaucoma therapy.

A Tiny Implant, A Huge Impact

The smallest known medical implant, The iStent® Trabecular Micro-Bypass Stent is revolutionizing glaucoma surgery and treatment as the first Micro-Invasive Glaucoma Surgery device. Developed by Glaukos® in 2012, The iStent® has been implanted in more than 300,000 eyes around the world since it was approved by the FDA in 2012.

 

The iStent®

 

The tiny device, only 1 mm x 0.33 mm, is designed to reduce intraocular pressure and dependence on ocular hypotensive medications in patients with mild-to-moderate open-angle glaucoma. Once implanted in the eye, the iStent® works to:

• Restore the eye’s natural ability to drain the fluid that increases intraocular pressure
• Maintain normal eye pressure
• Reduce or eliminate the need for glaucoma medications for some patients

Opening Eyes to Worlds of Possibility

For cataract patients who also are managing glaucoma, implantation of the iStent® during cataract surgery, offers the opportunity to address both medical conditions at the same time.

See how The iStent® works.

 

To learn more about Glaukos® Corporation of Laguna Hills, Calif., and how the iStent® may benefit your patients, visit the company’s website HERE.